Last reviewed · How we verify
LEO32731
At a glance
| Generic name | LEO32731 |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) (PHASE2)
- Study to Assess the Efficacy and Safety of Orismilast in Psoriasis (PHASE2)
- Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects. (PHASE1)
- A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People (PHASE1)
- Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam (PHASE1)
- LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris (PHASE2)
- An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD) (PHASE1)
- LEO 32731 - A Phase I Study in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO32731 CI brief — competitive landscape report
- LEO32731 updates RSS · CI watch RSS
- LEO Pharma portfolio CI